TLSA announces BIO-Europe 2025 presentation in Vienna, Nov 3–5

Rhea-AI Filing Summary

Tiziana Life Sciences (TLSA) announced it will participate as a presenting company at BIO-Europe 2025, described as Europe’s premier life sciences partnering conference.

The event will be held November 3–5, 2025, at the Vienna Exhibition and Congress Center (Messe Wien) in Vienna, Austria. The related press release was furnished as Exhibit 99.1 and is not deemed filed under Section 18 of the Exchange Act.

Form 6-K: How Foreign Companies Report to the SEC →

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13a-16 OR 15d-16

UNDER THE SECURITIES EXCHANGE ACT OF 1934

October 2025

Commission File Number: 001-38723

Tiziana Life Sciences LTD

(Exact Name of Registrant as Specified in Its Charter)

9^th Floor

107 Cheapside

London

EC2V 6DN

(Address of registrant’s principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F ☒       Form 40-F ☐

INFORMATION CONTAINED IN THIS REPORT ON FORM 6-K

On October 29, 2025, Tiziana Life Sciences LTD (the “Company”) issued this 6K announcing, its participation as a presenting company at BIO-Europe 2025. The event, Europe’s premier life sciences partnering conference, will take place November 3–5, 2025, at the Vienna Exhibition and Congress Center (Messe Wien) in Vienna, Austria.

The Announcement is furnished herewith as Exhibit 99.1 to this Report on Form 6-K. The information in the attached Exhibits 99.1 is being furnished and shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, or otherwise subject to the liabilities of that Section, nor shall it be deemed incorporated by reference in any filing made by the Company under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, except as otherwise set forth herein or as shall be expressly set forth by specific reference in such a filing.

1

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	TIZIANA LIFE SCIENCES LTD
Date: October 29, 2025	By:	/s/ Keeren Shah
		Name:	Keeren Shah
		Title:	Chief Financial Officer

2

EXHIBIT INDEX

Exhibit No.		Description
99.1		Tiziana Life Sciences LTD Press Release, dated October 29, 2025

3

FAQ

What did TLSA announce in this Form 6-K?

TLSA announced its participation as a presenting company at BIO-Europe 2025.

When and where is BIO-Europe 2025 taking place?

The conference is scheduled for November 3–5, 2025, at the Vienna Exhibition and Congress Center (Messe Wien) in Vienna, Austria.

How was the announcement provided to investors?

It was furnished via a Form 6-K with the press release attached as Exhibit 99.1.

Is the information considered filed under Section 18 of the Exchange Act?

No. The information is furnished and is not deemed filed under Section 18.

Which exhibit contains the press release?

The press release is included as Exhibit 99.1.

Does the filing include financial results or transaction details?

No. It communicates TLSA’s planned presentation at BIO-Europe 2025.